Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG348 in Advanced Solid Tumors
NCT06065059Phase 2Terminated
- Sponsor
- Tango Therapeutics
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TNG348 in breast cancer, ovarian cancer, pancreatic cancer (PC), prostate cancer (PCa), solid tumor, sponsored by Tango Therapeutics. Started Dec 2023; status: terminated.
02
Drugs
TNG348
03
Conditions
breast cancerovarian cancerpancreatic cancer (PC)prostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT06065059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065059.